Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacteroides xylanisolvens NSP003
- Development stage
- Preclinical
- Lead developer
- Nanchang University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Bacteroides xylanisolvens* NSP003 is a specific strain of gut commensal bacteria identified for its potential therapeutic role in treating ulcerative colitis. It is enriched by low-esterified pectin and has been studied as a live biotherapeutic product, both individually and as part of a microbial consortium. Mechanistically, it contributes to the amelioration of colitis by remodeling the gut microbiome (increasing propionic acid levels), modulating intestinal homeostasis through the activation of PI3K/calcium signaling pathways, and reprogramming systemic metabolism, specifically increasing serum phenylethylamine levels. The strain was characterized by researchers at Nanchang University.
- Other names
- B. xylanisolvens NSP003
02
Targets
FFAR2PI3K (Phosphoinositide-3-kinase regulatory subunit 6)TAAR1 (Trace amine-associated receptor 1)
Beyond the preview
Go deeper on bacteroides xylanisolvens NSP003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacteroides xylanisolvens NSP003.